Skip to main content

Table 7 Pairwise league table of ACD and CVD

From: Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease

Comparisons for ACD (bottom left) and CVD (upper right) of the 8 interventions

Empagliflozin

1.11 (0.74,1.65)

1.09 (0.70,1.70)

1.12 (0.71,1.77)

1.14 (0.76,1.72)

1.13 (0.77,1.65)

1.40 (0.92,2.14)

0.88 (0.56,1.37)

1.28 (0.90,1.81)

1.02 (0.67,1.56)

Canagliflozin

0.99 (0.71,1.38)

1.02 (0.72,1.44)

1.03 (0.77,1.37)

1.02 (0.80,1.30)

1.27 (0.94,1.72)

0.79 (0.57,1.11)

1.16 (0.95,1.40)

1.06 (0.69,1.62)

1.04 (0.78,1.37)

Dapagliflozin

1.03 (0.69,1.54)

1.04 (0.74,1.48)

1.03 (0.76,1.41)

1.28 (0.89,1.84)

0.80 (0.54,1.18)

1.17 (0.89,1.54)

0.73 (0.41,1.30)

0.72 (0.45,1.16)

0.70 (0.43,1.12)

Ertugliflozin

1.01 (0.71,1.46)

1.00 (0.72,1.39)

1.25 (0.86,1.81)

0.78 (0.52,1.16)

1.14 (0.85,1.52)

0.86 (0.57,1.31)

0.85 (0.65,1.10)

0.82 (0.63,1.06)

1.18 (0.74,1.87)

Sotagliflozin

0.99 (0.76,1.28)

1.23 (0.90,1.69)

0.77 (0.54,1.09)

1.12 (0.91,1.39)

0.95 (0.64,1.41)

0.93 (0.74,1.16)

0.90 (0.72,1.13)

1.29 (0.83,2.02)

1.10 (0.90,1.35)

Finerenone

1.24 (0.94,1.64)

0.78 (0.57,1.06)

1.13 (0.98,1.31)

0.84 (0.55,1.28)

0.82 (0.63,1.08)

0.79 (0.61,1.04)

1.14 (0.71,1.83)

0.97 (0.76,1.25)

0.88 (0.71,1.10)

Exenatide

0.62 (0.43,0.90)

0.91 (0.72,1.15)

1.13 (0.73,1.73)

1.11 (0.83,1.47)

1.07 (0.80,1.42)

1.53 (0.95,2.48)

1.31 (1.00,1.70)

1.19 (0.94,1.50)

1.34 (1.02,1.77)

Liraglutide

1.46 (1.11,1.92)

0.85 (0.58,1.24)

0.83 (0.69,1.02)

0.81 (0.66,0.98)

1.16 (0.75,1.79)

0.99 (0.83,1.17)

0.90 (0.80,1.00)

1.01 (0.84,1.22)

0.76 (0.62,0.93)

Placebo

  1. RR with 95% CI